Last edited by Tokora
Saturday, August 1, 2020 | History

1 edition of Dyslipidemia found in the catalog.

Dyslipidemia

Miroslava KarapetroviДЌ

Dyslipidemia

causes, diagnosis, and treatment

by Miroslava KarapetroviДЌ

  • 214 Want to read
  • 2 Currently reading

Published by Nova Science Publishers in Hauppauge, N.Y .
Written in English

    Subjects:
  • Dyslipidemias,
  • HDL Lipoproteins,
  • Physiology

  • Edition Notes

    Includes bibliographical references and index.

    Statementeditors, Miroslava Karapetrovič and Zlatko Ačimovič
    The Physical Object
    Paginationp. ;
    ID Numbers
    Open LibraryOL25061232M
    ISBN 109781621009177
    LC Control Number2011040279

      A dyslipidemia diet is a diet aimed at dealing with dyslipidemia before it does too much damage to your body. But what is dyslipidemia?The medical dyslipidemia definition states that it is an excessive amount of lipids in the blood, which includes having high bad cholesterol (also known as low density lipoprotein; LDL) and triglycerides (a type of fat). Home > Books > Dyslipidemia. Downloaded: Abstract. The clinical presentations of atherosclerotic disease are the result of a constellation of diverse metabolic and immunologic mechanisms ultimately set into motion by the formation of fatty acid streaks and the accompanying inflammatory cell activation, endothelial damage, smooth muscle Cited by: 1.

      Management of Dyslipidemia in Adults in Red book. Montvale, N.J.: Medical Economics Data, Cost to the patient will be higher, depending on prescription filling fee. Cited by: Pathophysiology of Dyslipidemia in the Metabolic Syndrome Article Literature Review (PDF Available) in Postgraduate medical journal 81() July with 3, Reads.

    A person with dyslipidemia has abnormal levels of lipids—such as cholesterol and triglycerides— in their blood. Cholesterol comes in many forms: HDL is known as “good” cholesterol. Women with diabetes should keep their HDL levels above 50 mg/dl; above 40 mg/dl for men. The third edition of Hypertension: A Companion to Braunwald's Heart Disease, by Drs. George L. Bakris and Matthew Sorrentino, focuses on every aspect of managing and treating patients who suffer from hypertensive disorders. Designed for cardiologists, endocrinologists and nephrologists alike, this expansive, in-depth review boasts expert guidance from contributors worldwide, keeping you.


Share this book
You might also like
The Windsor Protocol

The Windsor Protocol

Billy Boy

Billy Boy

Man, morals and society

Man, morals and society

Northern Ireland progress

Northern Ireland progress

research program of the Nuclear Regulatory Commission

research program of the Nuclear Regulatory Commission

Smith & Robersons Business Law S/g

Smith & Robersons Business Law S/g

Historical dictionary of U.S. diplomacy since the Cold War

Historical dictionary of U.S. diplomacy since the Cold War

Flows and Stocks of Fixed Capital 1970-1995

Flows and Stocks of Fixed Capital 1970-1995

Milestones in impact assessment research in the CGIAR, 1970-1999

Milestones in impact assessment research in the CGIAR, 1970-1999

Pv-Double Dragon -Op/16

Pv-Double Dragon -Op/16

Recycling resources refuse

Recycling resources refuse

scope of trade-creating industrial co-operation at enterprise level between countries having different economic and social systems

scope of trade-creating industrial co-operation at enterprise level between countries having different economic and social systems

Catalogue of mammalia in the Indian Museum, Calcutta

Catalogue of mammalia in the Indian Museum, Calcutta

Experimental methods to reduce windthrow in a streamside buffer

Experimental methods to reduce windthrow in a streamside buffer

Dyslipidemia by Miroslava KarapetroviДЌ Download PDF EPUB FB2

Reflecting current guidelines from the National Cholesterol Education Program, the book explains why, when, and how to treat dyslipidemia. Dyslipidemia book includes dietary treatment, drug treatment, and Dyslipidemia book for special populations such as patients with coronary heart disease, patients at high risk for coronary heart disease, patients with diabetes, women, older adults, young adults, and racial Format: Hardcover.

An ideal reference for practitioners and health care professionals who care for patients with abnormal lipids, Dyslipidemia: A Clinical Approach provides clinically relevant, user-friendly information on all aspects of this rapidly evolving field. In addition to concise yet in-depth coverage of key topics, chapters include background information, evidence from the literature, and author commentary on conflicting or Price: $ Various experimental and clinical researches are going on related to the basic mechanisms and treatment of dyslipidemia.

This book will deliver an overview of dyslipidemia from distinct facets of physiopathology, ethnic differences, genetics and role in metabolic syndrome.1/5(1). In this book, we assembled a group of world-renowned scholars in their field to address major areas in lipoprotein disorders Dyslipidemia is a major Dyslipidemia book factor for cardiovascular disease, which is the leading cause of morbidity and mortality around the globe, particularly among aging populations.

Dyslipidemia Pocketcard Set 1st Edition by Borm Bruckmeier Publishing (Author) out of 5 stars 11 ratings. ISBN ISBN Why is ISBN important. ISBN. This bar-code number lets you verify that you're getting exactly the right version or edition of a book. /5(10). The John Hopkins Textbook of Dyslipidemia by Peter O.

Kwiterovich and Kwiterovich Jr. MD, Peter O. Statin-Ease® Muscle Pain Relief – Natural Supplement Combo, % Drug-Free, with CoQ10, Vitamin D, Magnesium, Carnitine, Citrulline & Other Key Ingredients, 30 stickpacks, Juicy Orange 25% coupon applied.

Abnormalities in lipid metabolism are very commonly observed in obese patients. Approximately % of obese patients are dyslipidemic. The lipid abnormalities in obese patients include elevated serum triglyceride, VLDL, apolipoprotein B, and non-HDL cholesterol levels. The increase in serum triglycerides is primarily due to increased hepatic production of VLDL but a decrease in the clearance Cited by: Pediatric primary or monogenic dyslipidemias are a heterogeneous group of disorders, characterized by severe elevation of cholesterol, triglycerides or rarely a combination of the two.

Monogenic hypercholesterolemias have elevated low-density lipoprotein-cholesterol (LDL-C) levels and very high risk of premature atherosclerotic disease.

They are caused by mutations in genes involved in the. Dyslipidemia Guidelines (,and ). These recommendations are intended to provide a reasonable and practical approach to care for specialists, physicians and allied health professionals. They are subject to change as scientific knowledge and technology advance andFile Size: 2MB.

Treatment Overview of Dyslipidemia Dyslipidemia is a powerful risk factor for coronary heart disease (CHD). Clinical trials conclusively have demonstrated that treatment of lipid disorders can reduce CHD morbidity and mortality.

Treatment of lipid disorders also helps prevent stroke and peripheral arterial disease. Basic Size: KB. Dyslipidemia is divided up into primary and secondary types. Primary dyslipidemia is inherited. Secondary dyslipidemia is an acquired condition.

That Author: James Roland. Several experimental and clinical studies are still being conducted regarding the underlying mechanisms and treatment of dyslipidemia. The current book is providing a general overview of dyslipidemia from diverse aspects of pathophysiology, ethnic differences, prevention, health hazards, and by: 7.

Dyslipidemia is a major risk factor for atherosclerosis. Atherosclerosis is a disease process that affects the coronary, cerebral and peripheral arterial circulation. Coronary Heart Disease (CHD) The etiology of atherosclerosis is multifactorial but the cause-effect relationship between dyslipidemia and File Size: 2MB.

The book is tailored to the needs of busy health care professionals treating patients in various clinical settings, and focuses on presenting essential information to clinicians who are at the.

Dyslipidemia’s contribution to stroke varies across subtypes, and the association between dyslipidemia and ischemic stroke caused by atherosclerosis is the most well known. Dyslipidemia is an important risk factor for atherosclerotic ischemic stroke, and multiple clinical trials have shown that aggressive statin therapy can lower the Cited by: 6.

Diabetes is an especially significant secondary cause because patients tend to have an atherogenic combination of high TGs; high small, dense LDL fractions; and low HDL (diabetic dyslipidemia, hypertriglyceridemic hyperapo B).

Patients with type 2 diabetes are especially at risk. The combination may be a consequence of obesity, poor control of diabetes, or both, which may increase circulating. Secondary forms of dyslipidemia also exist, and several drug classes may elevate cholesterol levels (eg, progestins, thiazide diuretics, glucocorticoids, β-blockers, isotretinoin, protease inhibitors, cyclosporine, mirtazapine, and sirolimus).

The primary defect in familial hypercholesterolemia is inability to bind LDL to the LDL receptor (LDL-R). The initial step is to decide which particular lipid/lipoprotein abnormalities need to be evaluated and whether they need treatment. These disorders can be divided into elevations of plasma LDL, elevations of plasma triglycerides, and decreases in plasma HDL.

Frequently a patient can have multiple lipid/lipoprotein abnormalities. The next step is to rule out secondary causes that could account Cited by: 1. Dyslipidemia-related complications (e.g., heart disease, stroke) year atherosclerotic cardiovascular disease (ASCVD) risk assessment (only if primary prevention) Current medications that may contribute to dyslipidemia.

LDL-C reduction based on statin benefit group, if applicable to patient (see Table ). The Primary Hyperlipidemia Clinical Topic Collection gathers the latest guidelines, news, JACC articles, education, meetings and clinical images pertaining to its cardiovascular topical area — all in one place for your convenience.

Mark Houston MD, MS, MSc, in Integrative Medicine (Fourth Edition), Nutrition. Nutrition is an important treatment for dyslipidemia, CHD risk factors, and the prevention and treatment of us epidemiological studies and prospective clinical trials, including the Framingham Heart Study, 54,55 Seven Countries Study, 56,57 Pritikin diet studies, Ornish Lifestyle Heart.Chronic kidney disease (CKD) is associated with a dyslipidemia comprising high triglycerides, low HDL-cholesterol and altered lipoprotein composition.

Cardiovascular diseases are the leading cause of mortality in CKD, especially in end stage renal disease patients. Thus, therapies to reduce cardiovascular risk are urgently needed in CKD. Robust clinical trial evidence has found that use of Cited by: 9.The first comprehensive text on dyslipidemia from a major academic institution, this book covers all aspects of dyslipidemia as it relates to human disease, including coronary artery disease, cerebrovascular disease, peripheral vascular disease, and pancreatitis.

The material is presented in a.